Based on our proprietary Fab-like bispecific format (bsFab) and previously characterized anti-MSLN [clone A1, (23)] and anti-CD16 [clone C21, (24)] nanobodies, we designed a bsFab (MesobsFab) targeting mesothelin positive tumor cells and CD16 positive immune cells (Figure S1A). Here, FCGR3A is linked to neoplasm.